Positions

Overview

  • Dr. Prabhu received a BS degree in Science from Penn State University and his MD degree from Jefferson Medical College in Philadelphia. He did internal medicine residency and a basic research fellowship at the University of Pittsburgh and cardiovascular disease fellowship at the University of Texas Health Science Center at San Antonio. He was a cardiology faculty there as well as at the University of Louisville, before his arrival to UAB as Director of the Division of Cardiovascular Disease. At UAB, he is also Director of the Comprehensive Cardiovascular Center. Dr. Prabhu serves on the Editorial Board of several cardiovascular journals. He is a member of the American Society for Clinical Investigation.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes.Hypertension.  72:343-349. 2018
    2018 Genetic deletion of 12/15 lipoxygenase promotes effective resolution of inflammation following myocardial infarction.Journal of Molecular and Cellular Cardiology.  118:70-80. 2018
    2018 CCR2+ Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload.JACC: Basic to Translational Science.  3:230-244. 2018
    2018 Effect of NT-proBNP-Guided Therapy on All-Cause Mortality in Chronic Heart Failure With Reduced Ejection Fraction.Journal of the American College of Cardiology.  71:951-952. 2018
    2018 Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.JAMA Cardiology.  3:11-17. 2018
    2018 THE CARDIOSPLENIC AXIS IS ESSENTIAL FOR THE PATHOGENESIS OF ISCHEMIC HEART FAILURE.Transactions- American Clinical and Climatological Association.  129:202-214. 2018
    2018 The stress kinase JNK regulates gap junction Cx43 gene expression and promotes atrial fibrillation in the aged heart.Journal of Molecular and Cellular Cardiology.  114:105-115. 2018
    2017 Resolution Agonist 15-epi-Lipoxin A4 Programs Early Activation of Resolving Phase in Post-Myocardial Infarction Healing.Scientific Reports.  7:9999. 2017
    2017 Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering.Journal of the American College of Cardiology.  70:766-775. 2017
    2017 Interaction of 12/15-lipoxygenase with fatty acids alters the leukocyte kinetics leading to improved postmyocardial infarction healing.AJP - Heart and Circulatory Physiology.  313:H89-H102. 2017
    2017 Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  6. 2017
    2017 Immunomodulation Is the Key to Cardiac Repair.Circulation Research.  120:1530-1532. 2017
    2017 Cardiomyocyte Ogt limits ventricular dysfunction in mice following pressure overload without affecting hypertrophy.Basic Research in Cardiology.  112:23. 2017
    2017 Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure.Circulation: Heart Failure.  10:e003688. 2017
    2017 Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure.Basic Research in Cardiology.  112:19. 2017
    2017 Myocardial ischemia/reperfusion impairs neurogenesis and hippocampal-dependent learning and memory.Brain, Behavior, and Immunity.  61:266-273. 2017
    2017 Continuous-Flow Left Ventricular Assist Device Support Improves Myocardial Supply:Demand in Chronic Heart Failure.Annals of Biomedical Engineering.  45:1475-1486. 2017
    2017 Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone.International Journal of Cardiology.  227:462-466. 2017
    2017 Cardiac inflammation in genetic dilated cardiomyopathy caused by MYBPC3 mutation.Journal of Molecular and Cellular Cardiology.  102:83-93. 2017
    2017 Mononuclear Phagocytes Are Dispensable for Cardiac Remodeling in Established Pressure-Overload Heart Failure.PLoS ONE.  12:e0170781. 2017
    2016 TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate.AJP - Heart and Circulatory Physiology.  311:H1189-H1201. 2016
    2016 Aging dysregulates D- and E-series resolvins to modulate cardiosplenic and cardiorenal network following myocardial infarction.Aging.  8:2611-2634. 2016
    2016 The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.Circulation Research.  119:91-112. 2016
    2016 Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.American Journal of Medicine.  129:1067-1073. 2016
    2016 Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.American Journal of Cardiology.  118:232-236. 2016
    2016 Acute Metabolic Influences on the Natriuretic Peptide System in Humans.Journal of the American College of Cardiology.  67:804-812. 2016
    2016 Heme oxygenase-1 regulates mitochondrial quality control in the heart.JCI insight.  1:e85817. 2016
    2015 Altered myocardial metabolic adaptation to increased fatty acid availability in cardiomyocyte-specific CLOCK mutant mice.BBA - Biochimica et Biophysica Acta.  1861:1579-1595. 2015
    2015 Cardiomyocyte-specific Bmal1 deletion in mice triggers diastolic dysfunction, extracellular matrix response, and impaired resolution of inflammation.AJP - Heart and Circulatory Physiology.  309:H1827-H1836. 2015
    2015 Residential Proximity to Major Roadways Is Associated With Increased Levels of AC133+ Circulating Angiogenic Cells.Arteriosclerosis, Thrombosis, and Vascular Biology.  35:2468-2477. 2015
    2015 Genetic Deficiency of Glutathione S-Transferase P Increases Myocardial Sensitivity to Ischemia-Reperfusion Injury.Circulation Research.  117:437-449. 2015
    2015 Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure.American Journal of Medicine.  128:715-721. 2015
    2015 Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function.Journal of Molecular and Cellular Cardiology.  84:24-35. 2015
    2015 Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice.Toxicology and Applied Pharmacology.  285:136-148. 2015
    2015 Pretransplant coagulopathy and in-hospital outcomes among heart transplant recipients: a propensity-matched nationwide inpatient sample study.Clinical Cardiology.  38:300-308. 2015
    2015 Reply: Upgrade ambulatory extra-aortic counterpulsation to full-support LVAD.JACC: Heart Failure.  3:343-344. 2015
    2015 Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST).Circulation: Heart Failure.  8:17-24. 2015
    2015 O-GlcNAcylation Negatively Regulates Cardiomyogenic Fate in Adult Mouse Cardiac Mesenchymal Stromal Cells.PLoS ONE.  10:e0142939. 2015
    2014 Ambulatory extra-aortic counterpulsation in patients with moderate to severe chronic heart failure.JACC: Heart Failure.  2:526-533. 2014
    2014 Impact of atrial fibrillation and heart failure, independent of each other and in combination, on mortality in community-dwelling older adults.American Journal of Cardiology.  114:909-913. 2014
    2014 Complement component 3 is necessary to preserve myocardium and myocardial function in chronic myocardial infarction.STEM CELLS.  32:2502-2515. 2014
    2014 Acrolein exposure is associated with increased cardiovascular disease risk.Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  3. 2014
    2014 Metabolomic analysis of pressure-overloaded and infarcted mouse hearts.Circulation: Heart Failure.  7:634-642. 2014
    2014 Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).American Journal of Cardiology.  114:79-82. 2014
    2014 It takes two to tango: monocyte and macrophage duality in the infarcted heart.Circulation Research.  114:1558-1560. 2014
    2014 Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure.American Journal of Medicine.  127:132-139. 2014
    2014 Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis.Circulation Research.  114:266-282. 2014
    2014 Impact of atrial fibrillation and heart failure, independent of each other and in combination, on mortality in community-dwelling older adults.American Journal of Cardiology.  114:909-913. 2014
    2014 Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction.Basic Research in Cardiology.  109:444. 2014
    2014 Inhibiting Na+/K+ ATPase can impair mitochondrial energetics and induce abnormal Ca2+ cycling and automaticity in guinea pig cardiomyocytes.PLoS ONE.  9:e93928. 2014
    2013 Bovine model of chronic ischemic cardiomyopathy: implications for ventricular assist device research.Artificial Organs.  37:E202-E214. 2013
    2013 Cardiac immune cell remodeling after myocardial infarction.Journal of Molecular and Cellular Cardiology.  62:142-143. 2013
    2013 Heme oxygenase-1 expression protects the heart from acute injury caused by inducible Cre recombinase.Laboratory Investigation.  93:868-879. 2013
    2013 Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells.STEM CELLS.  31:765-775. 2013
    2013 H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase.Circulation.  127:1116-1127. 2013
    2012 Reply to the editorJournal of Thoracic and Cardiovascular Surgery.  144:1531-1533. 2012
    2012 Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion.Basic Research in Cardiology.  107:305. 2012
    2012 Mechanism of myocardial ischemia with an anomalous left coronary artery from the right sinus of Valsalva.Journal of Thoracic and Cardiovascular Surgery.  144:402-408. 2012
    2012 O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.AJP - Heart and Circulatory Physiology.  302:H2122-H2130. 2012
    2012 Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner.Journal of the American College of Cardiology.  59:1477-1486. 2012
    2012 Statistical Analysis of Repeated MicroRNA High-Throughput Data with Application to Human Heart Failure: A Review of Methodology.Open Access Medical Statistics.  2012:21-31. 2012
    2012 Direct measurement of blood flow in microvessels grown in Matrigel in vivo.Journal of Surgical Research.  172:e55-e60. 2012
    2011 Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy.AJP - Heart and Circulatory Physiology.  301:H2050-H2060. 2011
    2011 Tumor necrosis factor receptor 2 signaling limits β-adrenergic receptor-mediated cardiac hypertrophy in vivo.Basic Research in Cardiology.  106:1193-1205. 2011
    2011 Microfluidic endothelial cell culture model to replicate disturbed flow conditions seen in atherosclerosis susceptible regions.Biomicrofluidics.  5:32006-3200611. 2011
    2011 Mitral valve prolapse after long-term mechanical ventricular unloading.The Journal of heart transplantation.  30:1067-1068. 2011
    2011 Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy.Journal of Molecular and Cellular Cardiology.  50:928-938. 2011
    2011 Heart transplant vs left ventricular assist device in heart transplant-eligible patients.Annals of Thoracic Surgery.  91:1330-1333. 2011
    2011 Endothelial cell culture model for replication of physiological profiles of pressure, flow, stretch, and shear stress in vitro.Analytical Chemistry.  83:3170-3177. 2011
    2011 Bovine model of doxorubicin-induced cardiomyopathy.Journal of Biomedicine and Biotechnology.  2011:758736. 2011
    2011 Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure.Cardiovascular Research.  89:129-138. 2011
    2011 Endothelial cell culture model of carotid artery atherosclerosis.Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  2011:186-189. 2011
    2011 Environmental pollutants and heart failureIssues in Toxicology.  177-197. 2011
    2011 Response to Letter to the Editor: A Novel Subcutaneous Counterpulsation Device: Acute Hemodynamic Efficacy During Pharmacologically Induced Hypertension, Hypotension, and Heart FailureArtificial Organs.  35:93-95. 2011
    2010 O-linked β-N-acetylglucosamine transferase is indispensable in the failing heart.Proceedings of the National Academy of Sciences.  107:17797-17802. 2010
    2010 Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction.Journal of Molecular and Cellular Cardiology.  49:587-597. 2010
    2010 EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling.Journal of Molecular and Cellular Cardiology.  49:655-663. 2010
    2010 Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation.AJP - Heart and Circulatory Physiology.  299:H1242-H1254. 2010
    2010 Microfluidic cardiac cell culture model (μCCCM).Analytical Chemistry.  82:7581-7587. 2010
    2010 Hemodynamic responses to continuous versus pulsatile mechanical unloading of the failing left ventricle.ASAIO Journal.  56:410-416. 2010
    2010 Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload.Free Radical Biology and Medicine.  49:401-407. 2010
    2010 A novel subcutaneous counterpulsation device: acute hemodynamic efficacy during pharmacologically induced hypertension, hypotension, and heart failure.Artificial Organs.  34:537-545. 2010
    2010 Erythropoietin and ventricular remodelling: a VEGF-dependent neovascularity.Cardiovascular Research.  87:6-7. 2010
    2010 Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart.Circulation.  121:1912-1925. 2010
    2010 WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death.Cellular Signalling.  22:809-820. 2010
    2009 O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death.AJP - Heart and Circulatory Physiology.  297:H1711-H1719. 2009
    2009 Neutralization of interleukin-18 ameliorates ischemia/reperfusion-induced myocardial injury.Journal of Biological Chemistry.  284:7853-7865. 2009
    2009 Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation.Circulation.  119:1386-1397. 2009
    2009 Intraoperative evaluation of the HeartMate II flow estimator.The Journal of heart transplantation.  28:39-43. 2009
    2009 Microfluidic cardiac circulation model (microCCM) for functional cardiomyocyte studies.Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.  2009:1060-1063. 2009
    2008 Human, bovine and porcine systematic vascular input impedances are not equivalent: implications for device testing and xenotransplantation in heart failure.The Journal of heart transplantation.  27:1340-1347. 2008
    2008 Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition.Circulation.  118:1970-1978. 2008
    2008 Acute hemodynamic efficacy of a 32-ml subcutaneous counterpulsation device in a calf model of diminished cardiac function.ASAIO Journal.  54:578-584. 2008
    2008 Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression.Journal of Biological Chemistry.  283:24889-24898. 2008
    2008 Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.Journal of the American College of Cardiology.  52:655-666. 2008
    2008 Postnatal intermittent hypoxia and developmental programming of hypertension in spontaneously hypertensive rats: the role of reactive oxygen species and L-Ca2+ channels.Hypertension.  52:156-162. 2008
    2008 Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection.Journal of Molecular and Cellular Cardiology.  44:1016-1022. 2008
    2008 Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts.AJP - Heart and Circulatory Physiology.  294:H2078-H2087. 2008
    2007 Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure.AJP - Heart and Circulatory Physiology.  293:H3673-H3684. 2007
    2007 Downregulation of CuZn-superoxide dismutase contributes to beta-adrenergic receptor-mediated oxidative stress in the heart.Cardiovascular Research.  74:445-455. 2007
    2007 Altered left ventricular-arterial coupling precedes pump dysfunction in early heart failure.Heart and Vessels.  22:170-177. 2007
    2007 Vascular pulsatility in patients with a pulsatile- or continuous-flow ventricular assist device.Journal of Thoracic and Cardiovascular Surgery.  133:517-524. 2007
    2007 Diabetic Cardiomyopathy in OVE26 Mice Shows Mitochondrial ROS Production and Divergence Between In Vivo and In Vitro Contractility.Review of Diabetic Studies.  4:159-168. 2007
    2006 Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function.Circulation Research.  98:1098-1105. 2006
    2006 Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation.Circulation.  113:544-554. 2006
    2006 Prolonged oxidative stress inverts the cardiac force-frequency relation: role of altered calcium handling and myofilament calcium responsiveness.Journal of Molecular and Cellular Cardiology.  40:64-75. 2006
    2005 Allopurinol and heart failure: a new use for an old drug?Journal of Molecular and Cellular Cardiology.  39:407-409. 2005
    2005 Post-infarction ventricular remodeling: an array of molecular events.Journal of Molecular and Cellular Cardiology.  38:547-550. 2005
    2005 Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function.Proceedings of the National Academy of Sciences.  102:3766-3771. 2005
    2004 Cytokine-induced modulation of cardiac function.Circulation Research.  95:1140-1153. 2004
    2004 Cardiac functional analysis by electrocardiography, echocardiography and in situ hemodynamics in streptozotocin-induced diabetic miceJournal of Health Science -Tokyo-.  50:356-365. 2004
    2004 Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB.Biochemical and Biophysical Research Communications.  319:304-311. 2004
    2004 Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart.Circulation Research.  94:1155-1157. 2004
    2004 Strategies for developing biomarkers of heart failure.Clinical Chemistry.  50:265-278. 2004
    2003 Beta-adrenergic receptor blockade modulates Bcl-X(S) expression and reduces apoptosis in failing myocardium.Journal of Molecular and Cellular Cardiology.  35:483-493. 2003
    2003 β-Adrenergic receptor blockade modulates Bcl-XSexpression and reduces apoptosis in failing myocardiumJournal of Molecular and Cellular Cardiology.  35:483-493. 2003
    2003 Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism.Circulation Research.  92:741-748. 2003
    2003 Cardiac toxic effects of trans-2-hexenal are mediated by induction of cardiomyocyte apoptotic pathways.Cardiovascular Toxicology.  3:341-351. 2003
    2002 Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: Role of aldose reductaseAJP - Heart and Circulatory Physiology.  283. 2002
    2002 Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase.AJP - Heart and Circulatory Physiology.  283:H2612-H2619. 2002
    2002 Images in cardiology: Anomalous origin of a diseased left main coronary artery from the right sinus of valsalva.Clinical Cardiology.  25:489. 2002
    2002 Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor.Circulation Research.  91:165-172. 2002
    2000 Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression.Circulation.  101:2338-2341. 2000
    2000 beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling.Circulation.  101:2103-2109. 2000
    2000 β-Adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide, and remodelingCirculation.  101:2103-2109. 2000
    2000 Altered LV inotropic reserve and mechanoenergetics early in the development of heart failureAJP - Heart and Circulatory Physiology.  278. 2000
    2000 Altered LV inotropic reserve and mechanoenergetics early in the development of heart failure.AJP - Heart and Circulatory Physiology.  278:H698-H705. 2000
    1999 Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-alpha-induced myodepression.Cardiovascular Research.  44:527-535. 1999
    1999 Nitric oxide effects on myocardial function and force-interval relations: regulation of twitch duration.Journal of Molecular and Cellular Cardiology.  31:2077-2085. 1999
    1999 Load sensitivity of left ventricular relaxation in normal and failing hearts: evidence of a nonlinear biphasic response.Cardiovascular Research.  43:354-363. 1999
    1998 Ryanodine and the left ventricular force-interval and relaxation-interval relations in closed-chest dogs: insights on calcium handling.Cardiovascular Research.  40:483-491. 1998
    1997 Ryanodine and left ventricular function in intact dogs: Dissociation of force-based and velocity-based indexesAJP - Heart and Circulatory Physiology.  42. 1997
    1997 Ryanodine and left ventricular function in intact dogs: dissociation of force-based and velocity-based indexes.American Journal of Physiology.  273:H1561-H1568. 1997
    1997 Syncope: current diagnosis and treatment.Current Problems in Cardiology.  22:242-296. 1997
    1997 Syncope: current diagnosis and treatment.Current Problems in Cardiology.  22:242-296. 1997
    1995 Postextrasystolic mechanical restitution in closed-chest dogs. Effect of heart failure.Circulation.  92:2652-2659. 1995
    1995 Effect of tachycardia heart failure on the restitution of left ventricular function in closed-chest dogs.Circulation.  91:176-185. 1995
    1993 Left ventricular energetics in closed-chest dogs.American Journal of Physiology.  265:H1048-H1055. 1993
    1993 An analysis of variability of left ventricular pressure decay.American Journal of Physiology.  264:H262-H268. 1993
    1992 Kinetics of restitution of left ventricular relaxation.Circulation Research.  70:29-38. 1992

    Chapter

    Year Title Altmetric
    2014 Pharmacological Models of Hypertrophy and Failure.  170-6. 2014
    2012 Chest Pain.  259-272. 2012
    2011 Environmental Pollutants and Heart Failure.  177-197. 2011
    2005 Chest Pain.  219-229. 2005
    1998 Faintness and syncope.  952-957. 1998
    1998 Palpitations.  130-131. 1998
    1997 Mitral Valve Prolapse.  10.1-10.18. 1997
    1996 Elastance based mechanical restitution provides data from the intact heart not available from any other technique.  293-300. 1996
    1995 Observations on the relation of PVA and MVO2 in closed-chest dogs.  79-89. 1995
    1994 Cardiovascular physiology.  2-14. 1994
    1993 Diseases of the heart.  18-89. 1993

    Research Overview

  • Dr. Prabhu's research focus has been to understand the fundamental mechanisms of pathological remodeling in the failing heart, with a particular focus on inflammatory pathways (tumor necrosis factor, nuclear factor-kappaB) and immune cells (e.g., macrophages, T-cells). He is also interested in the interplay between inflammatory signaling and stem cell-mediated repair of the failing heart. Clinical studies include profiling immune cell networks in human heart failure, and defining the effects of mechanical circulatory support on forward and reverse remodeling.
  • Principal Investigator On

  • Private Grant  awarded by TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D 2015 - 2023
  • Basic and Translational Science in Heart Failure  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2022
  • Genomic Analysis of Enhanced Response to Heart Failure Therapy in African America  awarded by University of Pittsburgh 2015 - 2019
  • Splenic Marginal Zone Macrophages in Chronic Ischemic Heart Failure  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2019
  • Private Grant  awarded by AASTROM BIOSCIENCES, INC. 2013 - 2018
  • Private Grant  awarded by ABBOTT LABORATORIES 2018
  • 6th Annual Comprehensive Cardiovascular Center (CCVC) Symposium: Focus on Cardiovascular Electrophysiology  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2018
  • Relationship between Coronary Flow Reserve, Myocardial Structure/Function and Glomerular Filtration Rates: Mechanistic Insights and Outcomes  awarded by American College of Cardiology 2018
  • Private Grant  awarded by BIOSENSE WEBSTER, INC. 2017
  • Private Grant  awarded by MEDTRONIC, INC. 2017
  • Private Grant  awarded by BOSTON SCIENTIFIC CORPORATION 2017
  • Protection of Ischemic Myocardium: Tumor Necrosis Factor Modulation of CPCs  awarded by University of Louisville 2011 - 2016
  • Role of T-Regulatory Lymphocytes in Pathological Cardiac Remodeling and Heart Failure  awarded by American Heart Association (Southeast Affiliate) 2014 - 2016
  • Obesity, Salt-Sensitivity, and Natriuretic Peptides  awarded by VANDERBILT UNIVERSITY 2015 - 2016
  • Role of Glutathione S-Transferase P in Heart Failure  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2012 - 2015
  • Role of Macrophages in Diabetic Cardiomyopathy  awarded by American Heart Association 2013 - 2014
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2012
  • Private Grant  awarded by THORATEC CORPORATION 2012
  • Private Grant  awarded by Gilead Sciences 2012
  • Investigator On

  • Integrated Cellular and Tissue Engineering for Ischemic Heart Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2023
  • Cardiac Mesenchymal Stem Cells and Myocardial Fibrosis: Role of Platelet Derived Growth Factor Receptor Signaling  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2021
  • Patient Oriented Research in Personalized Antithrombotic Therapy  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • Private Grant  awarded by ZOLL SERVICES, LLC 2018 - 2021
  • Resolution of Inflammation in Heart Failure Post-Myocardial Infarction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • Private Grant  awarded by HEARTWARE, INC. 2014 - 2021
  • Private Grant  awarded by GE HEALTHCARE 2016 - 2020
  • Beta-hydroxybutyrate Protects Mitochondria During Cardiac lschemla Reperfusion Injury  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2020
  • Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support  awarded by Northwestern University 2015 - 2020
  • Mitochondria-SR Redox Signaling and Ca2+ Handling in Healthy and Failing Hearts  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by LUNG BIOTECHNOLOGY PBC 2013 - 2019
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014 - 2019
  • Pathological TNFR1 Expressing CD4+ T-Cells are Critical for HF Progression  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2018
  • Reductive Stress Induces Proteotoxic Cardiac Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2018
  • Role of Lipoxins in Resolution of Inflammation Following Myocardial Infarction  awarded by American Heart Association (Southeast Affiliate) 2016 - 2018
  • Private Grant  awarded by GENO LLC 2015 - 2016
  • Private Grant  awarded by ARENA PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by ARENA PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by SUNSHINE HEART, INC. 2013 - 2016
  • Private Grant  awarded by CARDIACASSIST, INC 2015 - 2016
  • Private Grant  awarded by ABBOTT VASCULAR, INC. 2014 - 2015
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2013 - 2015
  • Private Grant  awarded by GENO LLC 2015
  • Training Program in Cardiovascular Pathophysiology  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2015
  • Role of Heme Oxygenase-1 in Doxorubicin-Induced Cardiac Toxicity  awarded by American Heart Association 2013 - 2015
  • Randomized Evaluation of VAD Intervention before Inotropic Therapy (REVIVE-IT) Pilot Trial  awarded by University of Michigan 2013 - 2015
  • Education And Training

  • Doctor of Medicine, Thomas Jefferson University
  • University of Pittsburgh, Internship 1986
  • University of Pittsburgh, Residency 1988
  • University of Texas Health Science Center, Postdoctoral Fellowship 1992
  • University of Pittsburgh, Postdoctoral Fellowship 1989
  • Full Name

  • Sumanth Prabhu
  • Blazerid

  • sprabhu